samedan logo
 
 
spacer
home > pmps > winter 2021 > how technology can help turn the tide on fake drugs in the covid-19 era
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

How Technology Can Help Turn the Tide on Fake Drugs in the COVID-19 Era

It is an unfortunate fact of industry that almost every sector of the global market is plagued by counterfeiting and the proliferation of knock-off products, created and sold by opportunistic or criminal enterprises. However, there are few in which the potential impact is as harmful to people as it is for the pharmaceutical sector.

Buying a fake consumer product is likely to be an expensive inconvenience at worst, but substandard or falsified medicines can pose a genuine threat to human health, as vulnerable patients are left with useless therapies that fail to treat their condition, or actively cause them harm. Against the backdrop of the current COVID-19 pandemic, this is a problem that is accelerating, and the consequences of this trend could be devastating.

To make matters worse, modern counterfeiting techniques are often quite sophisticated, making fake medicines harder than ever to detect, even without the supply chain disruptions brought about by the pandemic. International authorities are dedicating considerable time and resources to tackling the danger posed by counterfeit medicines, but the problem remains prominent.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mike Seed is a Sales and Product Manager at Elementar UK, a leading supplier of elemental analysis and IRMS (isotope-ratio mass spectrometer) instrumentation. He has been working with the company for nearly two decades, and has significant expertise in the development of stable isotope analysis techniques applied to a broad spectrum of applications.
spacer
Mike Seed
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

KKR Invests in Biosynth Carbosynth to Accelerate Growth and Help Build Global Life Sciences Tools Platform

London and Staad, 1 November 2021 KKR, a leading global investment firm, and Biosynth Carbosynth, a leading life sciences reagents and custom synthesis and manufacturing services company, announce today that KKR has agreed to acquire Biosynth Carbosynth from Armira and CEO Dr. Urs Spitz. Dr. Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on its next chapter of growth. Financial details of the transaction, which is subject to customary regulatory approvals, were not disclosed.
More info >>

White Papers

The EC Definition of a Nanomaterial - Potential Measurement Methodologies

NanoSight

In October 2011 the European Commission published a definition of Nanomaterials. This move followed more than six years of scientific consideration of the potential toxicological and environmental challenges posed by engineered nanomaterials.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement